6-(methylthio)quinazolin-4(3H)-one | 78299-51-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-(methylthio)quinazolin-4(3H)-one
• 英文别名: 6-(methylthio)-4-(3H)quinazolinone；6-(Methylthio)quinazolin-4(3h)-one；6-methylsulfanyl-3H-quinazolin-4-one
• CAS: 78299-51-1
• 化学式: C₉H₈N₂OS
• 分子量: 192.241
• InChiKey: MTLLYGIGUMMWBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(methylthio)quinazolin-4(3H)-one 在 三氯氧磷 作用下， 反应 3.0h， 以94%的产率得到4-chloro-6-(methylthio)quinazoline
  参考文献：
  名称：

  Cyclic GMP Phosphodiesterase Inhibitors. 2. Requirement of 6-Substitution of Quinazoline Derivatives for Potent and Selective Inhibitory Activity

  摘要：

  We synthesized various 4-[[3,4-(methylenedioxy)benzyl]amino]quinazolines substituted at the 5-to 8-positions and evaluated their inhibitory activities toward cyclic GMP phosphodiesterase (cGMP-PDE) from porcine aorta, Monosubstitution at the 6-position was essential for the inhibitory activity, and the preferred substituents were compact and hydrophobic: methoxy (3b, IC50 = 0.23 mu M), methyl (3c, 0.10 mu M), chloro (3d, 0.019 mu M), thiomethyl (3f, 0.031 mu M), and cyano (3p, 0.090 mu M) groups. Compounds 3b-d,f,p lacked inhibitory activity toward other PDE isozymes (all IC50 values > 100 mu M), and their relaxing activities in porcine coronary arteries were well correlated with the inhibitory activities toward cGMP-PDE (r = 0.88, p < 0.05). One of these compounds, 3b, elevated the intracellular cGMP level in isolated porcine coronary arteries without causing any change in the cAMP level. We consider that this series of compounds dilates coronary arteries via potent and specific inhibition of cGMP-PDE,

  DOI：

  10.1021/jm00039a024
• 作为产物：
  描述：

  5-氯-2-硝基苯甲酸 在 sodium sulfide 、 sodium hydroxide 作用下， 反应 7.5h， 生成 6-(methylthio)quinazolin-4(3H)-one
  参考文献：
  名称：

  (E)-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acids, a new series of antiallergy agents

  摘要：

  A series of substituted (E)-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acids was prepared and evaluated in the rat passive cutaneous anaphylaxis (PCA) test for antiallergic activity. Alkoxy, alkylthio, and isopropyl substituents at the 6- or 8-positions provided highly potent compounds. Conversion to the Z isomer, reduction of the side chain double bond, or reduction of the quinazoline ring resulted in substantial loss of activity. Among the analogues that exhibited oral activity in the PCA test, (E)-3-[6-(methylthio)-4-oxo-4H-quinazolin-3-yl]-2-propenoic acid (5i) was the most potent.

  DOI：

  10.1021/jm00357a018

文献信息

• New P2X3 receptor antagonists. Part 2: Identification and SAR of quinazolinones
  作者：Gábor Szántó、Attila Makó、István Vágó、Tamás Hergert、Imre Bata、Bence Farkas、Sándor Kolok、Mónika Vastag

  DOI：10.1016/j.bmcl.2016.07.013

  日期：2016.8

  Numerous potent P2X3 antagonists have been discovered and the therapeutic potential of P2X3 antagonism already comprises proof-of-concept data obtained in clinical trials with the most advanced compound. We have lately reported the discovery and optimization of thia-triaza-tricycle compounds with potent P2X3 antagonistic properties. This Letter describes the SAR of a back-up series containing a 4-oxo-quinazoline

  已经发现了许多有效的P2X3拮抗剂，P2X3拮抗作用的治疗潜力已经包括在最先进的化合物的临床试验中获得的概念验证数据。我们最近报道了具有有效P2X3拮抗特性的硫代-三氮杂-三环化合物的发现和优化。这封信描述了一个含有4-氧-喹唑啉中心环的备用序列的SAR。提出了高效化合物51的发现。
• Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US04281127A1

  公开（公告）日：1981-07-28

  Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives of the formula ##STR1## wherein R.sub.1 is hydrogen, lower alkyl, lower cycloalkyl, lower alkoxy, hydroxy, halo, lower alkykthio, lower alkylsulfinyl, lower alkylsulfonyl, di-(C.sub.1 -C.sub.7)alkyl-N(CH.sub.2).sub.n O-- or 2-hydroxyethoxy; R.sub.2 is hydrogen, lower alkyl or lower alkoxy; R.sub.3 is hydroxy, lower alkoxy, di-(C.sub.1 -C.sub.7)alkyl-N(CH.sub.2).sub.n O-- or di-(C.sub.1 -C.sub.7)alkyl-N(CH.sub.2).sub.n NH--; and n is 2 to 7; provided that at least one of R.sub.1 and R.sub.2 is other than hydrogen, when R.sub.3 is hydroxy, a salt thereof with a pharmaceutically acceptable base, or when R.sub.3 is di-(C.sub.1 -C.sub.7)alkyl-N(CH.sub.2).sub.n O-- or di-(C.sub.1 -C.sub.7)alkyl-N(CH.sub.2).sub.n NH--, a salt thereof with a pharmaceutically acceptable acid, and a process for the preparation thereof, are described. The compounds of formula I are useful as agents in the prevention of allergic reactions.

  公式为##STR1##的Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid衍生物，其中R.sub.1为氢、较低烷基、较低环烷基、较低烷氧基、羟基、卤素、较低烷硫基、较低烷基磺基、较低烷基砜基、二-(C.sub.1 -C.sub.7)烷基-N(CH.sub.2).sub.n O--或2-羟基乙氧基；R.sub.2为氢、较低烷基或较低烷氧基；R.sub.3为羟基、较低烷氧基、二-(C.sub.1 -C.sub.7)烷基-N(CH.sub.2).sub.n O--或二-(C.sub.1 -C.sub.7)烷基-N(CH.sub.2).sub.n NH--；n为2至7；要求至少R.sub.1和R.sub.2中的一个不是氢，当R.sub.3为羟基时，其与药用可接受的碱的盐，或当R.sub.3为二-(C.sub.1 -C.sub.7)烷基-N(CH.sub.2).sub.n O--或二-(C.sub.1 -C.sub.7)烷基-N(CH.sub.2).sub.n NH--时，其与药用可接受的酸的盐，以及其制备方法。公式I的化合物可用作预防过敏反应的药物。
• [EN] AMINO QUINAZOLINES AS KINASE INHIBITORS<br/>[FR] AMINO-QUINAZOLINES EN TANT QU'INHIBITEURS DE KINASE
  申请人：GLAXO GROUP LTD

  公开号：WO2013025958A1

  公开（公告）日：2013-02-21

  Disclosed are compounds having the formula (Formula (I)): wherein R1, R2, R3, and Z are as defined herein, and methods of making and using the same.

  揭示了具有以下公式（公式（I））的化合物：其中R1、R2、R3和Z如本文所定义，并且制备和使用这些化合物的方法。
• GYRASE INHIBITORS
  申请人：Creighton Christopher J.

  公开号：US20130079323A1

  公开（公告）日：2013-03-28

  Novel gyrase inhibitors and related compositions and methods are useful for impeding bacterial growth. Compounds of Formula (I), are disclosed: Formula (I), wherein Y is N or CH; Z is N or CR 5 ; R 5 is H, a substituted or unsubstituted hydrocarbyl residue (1-3C) containing 0-2 heteroatoms selected from O, S and N, or is an inorganic residue; L is O, S, NR 7 , or CR 8 R 9 ; R 7 is H or C 1-3 alkyl; R 8 and R 9 are each independently H or C 1-3 alkyl; R 2 is H, a hydrocarbyl residue (1-40C) containing 0-10 heteroatoms selected from O, S and N optionally substituted with an inorganic residue; R 4 is H, an inorganic residue, or a hydrocarbyl residue (1-30C) containing 0-12 heteroatoms selected from O, S and N and containing 0-10 inorganic residues, wherein R 5 and R 4 together may join to form a fused ring; and R 6 is selected from the group consisting of H, C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, halo C 1-5 alkyl, halo C 2-5 alkenyl, halo C 2-5 alkynyl, C 1-5 hydroxyalkyl, C 1-5 alkyl chloride, C 2-5 alkenyl chloride, and C 2-5 alkynyl chloride; or a pharmaceutically-acceptable salt, ester, or prodrug thereof.

  新型螺旋酶抑制剂及相关组合物和方法，适用于阻碍细菌生长。其中公开了式（I）的化合物：式（I），其中Y为N或CH；Z为N或CR5；R5为H，含有0-2个来自O、S和N的杂原子的取代或未取代的碳氢基残基（1-3C），或为无机残基；L为O、S、NR7或CR8R9；R7为H或C1-3烷基；R8和R9各自独立地为H或C1-3烷基；R2为H，含有0-10个来自O、S和N的杂原子的碳氢基残基（1-40C），可选地取代为无机残基；R4为H、无机残基或含有0-12个来自O、S和N的杂原子和含有0-10个无机残基的碳氢基残基（1-30C），其中R5和R4可以共同形成融合环；R6选自H、C1-5烷基、C2-5烯基、C2-5炔基、卤代C1-5烷基、卤代C2-5烯基、卤代C2-5炔基、C1-5羟基烷基、C1-5氯代烷基、C2-5氯代烯基和C2-5氯代炔基的群；或其药学上可接受的盐、酯或前药。
• Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
  申请人：Rice Kenneth D.

  公开号：US20140080810A1

  公开（公告）日：2014-03-20

  The invention is directed to Compounds of Formula I: (I) and pharmaceutically acceptable salts or solvates thereof, as well as methods of treating using the compounds, methods for screening for inhibitor compounds and methods for identifying treatment regimens.

  本发明涉及化合物I式：（I）及其药学上可接受的盐或溶剂化物，以及使用该化合物进行治疗的方法，筛选抑制剂化合物的方法和确定治疗方案的方法。